Diabète De Type 2
Articles

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?
Summary of The UK Prospective Diabetes Study (UKPDS).

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?
Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?
(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1
DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

The RESTORE-G Real World Evidence Study
RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?
Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.
Leave site modal
Vous êtes sur le point de quitter campus.sanofi/be. Sanofi n'est pas responsable du contenu de ce site externe.
Les contenus accessibles par ce site sont destinés exclusivement aux Professionnels de Santé.
Les contenus accessibles par ce site sont destinés
exclusivement aux Professionnels de Santé.
Sanofi met a votre disposition, sur un portail unique dédié aux professionnels de santé, des contenus exclusifs comprenant des contenus scientifiques et des outils pour votre pratique quotidienne.